221 related articles for article (PubMed ID: 34580053)
1. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
[TBL] [Abstract][Full Text] [Related]
3. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Machado A; Levental M; Ghai S; Chang SD; Patel C; Kassam Z; Loblaw A; Kebabdjian M; Pond G; Haider MA
Eur Urol Oncol; 2024 Jun; 7(3):456-461. PubMed ID: 37838556
[TBL] [Abstract][Full Text] [Related]
5. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
6. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial.
Möller F; Månsson M; Wallström J; Hellström M; Hugosson J; Arnsrud Godtman R
Eur Urol; 2024 Mar; ():. PubMed ID: 38490856
[TBL] [Abstract][Full Text] [Related]
8. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
[TBL] [Abstract][Full Text] [Related]
9. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
[TBL] [Abstract][Full Text] [Related]
10. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.
Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L
Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772
[TBL] [Abstract][Full Text] [Related]
12. Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy.
Godtman RA; Pettersson C; Svensson L; Kohestani K; Stinesen Bratt K; Wallström J; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2024 Jun; 7(3):553-562. PubMed ID: 37993370
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract][Full Text] [Related]
14. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
15. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
17. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
Bratt O; Godtman RA; Jiborn T; Wallström J; Akre O; Carlsson S; Nordström T; Thimansson E; Alterbeck M; Zackrisson S; Hugosson J; Bjartell A; Lantz A
Eur Urol; 2024 Mar; 85(3):207-214. PubMed ID: 38042646
[TBL] [Abstract][Full Text] [Related]
18. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.
Dieffenbacher S; Nyarangi-Dix J; Giganti F; Bonekamp D; Kesch C; Müller-Wolf MB; Schütz V; Gasch C; Hatiboglu G; Hauffe M; Stenzinger A; Duensing S; Schlemmer HP; Moore CM; Hohenfellner M; Radtke JP
Eur Urol Focus; 2021 Jan; 7(1):102-110. PubMed ID: 30878348
[TBL] [Abstract][Full Text] [Related]
19. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.
Israël B; Immerzeel J; van der Leest M; Hannink G; Zámecnik P; Bomers J; Schoots IG; van Basten JP; Debruyne F; van Oort I; Sedelaar M; Barentsz J
BJU Int; 2022 Apr; 129(4):480-490. PubMed ID: 34358388
[TBL] [Abstract][Full Text] [Related]
20. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
